Clinical Trials
24 trialsNCT06914479 2026-05-27
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT07346144 2026-05-04
ADePT
Trogenix ltd
Phase 1/2 Recruiting
NCT05536349 2026-04-30
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07332000 2026-03-20
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07363031 2026-01-23
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
Phase 2 Enrolling by invitation
NCT07294547 2025-12-19
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Phase NA Recruiting
NCT01436968 2025-07-30
PrTK03
Candel Therapeutics, Inc.
Phase 3 Active not recruiting
NCT02768363 2025-07-30
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Candel Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03131037 2025-07-11
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
Candel Therapeutics, Inc.
Phase 1 Completed
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT03004183 2024-10-15
STOMP
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00634231 2023-08-25
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Candel Therapeutics, Inc.
Phase 1 Completed
NCT00638612 2023-08-25
PaTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT00751270 2023-08-25
BrTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT01997190 2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT03541928 2021-04-06
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
The Methodist Hospital Research Institute
Phase 2 Unknown
NCT00042328 2015-08-24
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Baylor College of Medicine
Phase 2 Completed
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00274404 2011-10-27
Controlled Trial of Valacyclovir in Infectious Mononucleosis
University of Minnesota
Phase 1/2 Completed
NCT00045292 2010-09-21
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 3 Completed